Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Ipsen
  6. Summary
    IPN   FR0010259150

IPSEN

(IPN)
  Report
Real-time Euronext Paris  -  11:35 2022-07-01 am EDT
92.10 EUR   +2.28%
06/29Ipsen Wins US FDA's Priority Review Tag For Ultra-rare Genetic Disease Drug
MT
06/29Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission
CI
06/28Biopharma Credit Expects Up To $7 Million Loan Prepayment From Epizyme
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
06/27/2022 06/28/2022 06/29/2022 06/30/2022 07/01/2022 Date
85.55(c) 85.3(c) 89.35(c) 90.05(c) 92.1(c) Last
155 450 110 465 124 313 164 667 97 787 Volume
-2.67% -0.29% +4.75% +0.78% +2.28% Change
More quotes
Estimated financial data (e)
Sales 2022 2 902 M 3 018 M 3 018 M
Net income 2022 736 M 765 M 765 M
Net cash position 2022 576 M 599 M 599 M
P/E ratio 2022 10,6x
Yield 2022 1,28%
Sales 2023 2 972 M 3 091 M 3 091 M
Net income 2023 661 M 687 M 687 M
Net cash position 2023 1 173 M 1 220 M 1 220 M
P/E ratio 2023 11,5x
Yield 2023 1,29%
Capitalization 7 594 M 7 899 M 7 899 M
EV / Sales 2022 2,42x
EV / Sales 2023 2,16x
Nbr of Employees 5 744
Free-Float 41,8%
More Financials
Company
Ipsen specializes in the research, development, manufacturing and marketing of medications. Sales break down by family of products as follows: - specialty drugs (92.1%). Sales break down by therapeutic area between oncology (81.4%), neuroscience (1516.7 and rare diseases (1.9%); - consumer healthcare products (7.9%): products used in the treatment of gastrointestinal disorders, neurodegenerative pathologies and... 
Read more
Sector
Pharmaceuticals
Calendar
07/28Earnings Release
More about the company
Ratings of Ipsen
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about IPSEN
06/29Ipsen Wins US FDA's Priority Review Tag For Ultra-rare Genetic Disease Drug
MT
06/29Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patie..
CI
06/28Biopharma Credit Expects Up To $7 Million Loan Prepayment From Epizyme
MT
06/27SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Monday
MT
06/27Wall Street Set for Positive Open, Extending Gains on Easing Inflation Expectations
MT
06/27Top Premarket Gainers
MT
06/27TRANSCRIPT : Epizyme, Inc., Ipsen S.A. - M&A Call
CI
06/27European shares hit two-week high as China eases COVID-19 curbs
RE
06/27Epizyme Agrees to be Acquired by Ipsen for $247 Million
MT
06/27France's Ipsen Launches Tender Offer to Purchase US Biopharmaceutical Epizyme
MT
06/24IPSEN : Security operations
CO
06/09Ipsen receives positive opinion in Europe for Dysport in the management of urinary inco..
AQ
06/09Ipsen Granted Positive Opinion in EU For Urinary Incontinence Management Injection Dysp..
MT
06/09IPSEN : Rediffusion AG – 24 mai 2022 (2)
PU
06/03IPSEN : 2022 SM – Voting results
PU
More news
News in other languages on IPSEN
06/29Paris anxieuse
06/29ACTUALIZACIÓN DE LAS FUERTES VARIACI : las esperanzas de Just Eat se disparan, las de Cary..
06/29POINT SUR LES FORTES VARIATIONS DU J : les espoirs de Just Eat s'envolent, contrairement à..
06/29CAC40 : la prudence domine avant des statistiques majeures
06/29Paris repart à la baisse, inquiète de l'activité économique
More news
Analyst Recommendations on IPSEN
More recommendations
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Last Close Price 92,10 €
Average target price 102,50 €
Spread / Average Target 11,3%
EPS Revisions
Managers and Directors
David G. Loew Chief Executive Officer & Director
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Marc M. P. de Garidel Non-Executive Chairman
Aidan Murphy Executive Vice President-Technical Operations
Howard Mayer Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
IPSEN14.41%7 899
JOHNSON & JOHNSON3.76%472 389
PFIZER, INC.-11.21%293 506
ELI LILLY AND COMPANY17.38%292 291
ROCHE HOLDING AG-15.48%272 104
ABBVIE INC.13.59%271 782